Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer.

A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial. Br J Cancer (2005) 1.06

Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group. Br J Cancer (2002) 0.88

Resistance to platinum-containing chemotherapy in testicular germ cell tumors is associated with downregulation of the protein kinase SRPK1. Neoplasia (2004) 0.85

A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors. Invest New Drugs (2012) 0.84

Improving the outcome of salvage treatment for non-seminomatous germ cell tumours (NSGCT). Br J Cancer (2000) 0.78

Bleomycin, vincristine, cisplatin/bleomycin, etoposide, cisplatin chemotherapy: an alternating, dose intense regimen producing promising results in untreated patients with intermediate or poor prognosis malignant germ-cell tumours. Br J Cancer (2004) 0.78

Salvage chemotherapy with paclitaxel and gemcitabine plus nedaplatin (TGN) as part of multidisciplinary therapy in patients with heavily pretreated cisplatin-refractory germ cell tumors. Int J Clin Oncol (2009) 0.77

Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group. Br J Cancer (2003) 0.75

The role of high-dose chemotherapy in relapsed germ cell tumors. World J Urol (2004) 0.75

Salvage chemotherapy with gemcitabine plus oxaliplatin for patients with testicular germ cell cancer. Int J Clin Oncol (2014) 0.75

Successful treatment of disseminated extragonadal germ cell cancer with intensive conventional chemotherapy after first-line high-dose chemotherapy. Int J Clin Oncol (2006) 0.75

Lenalidomide in patients with cisplatin-refractory and multiply relapsed germ cell tumors. J Cancer Res Clin Oncol (2009) 0.75

Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori. Antimicrob Agents Chemother (1996) 6.01

Detection and identification of fungal pathogens in blood by using molecular probes. J Clin Microbiol (1997) 5.86

Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol (2000) 4.25

Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet (1998) 4.16

Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol (2002) 3.91

Treatment of older patients with mantle-cell lymphoma. N Engl J Med (2012) 3.46

Novel mechanism of macrolide resistance in Streptococcus pneumoniae. Diagn Microbiol Infect Dis (1996) 3.29

Retracted Reconstitution of hematopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex vivo. N Engl J Med (1995) 2.97

Pure red-cell aplasia associated with clonal expansion of granular lymphocytes expressing killer-cell inhibitory receptors. N Engl J Med (1999) 2.89

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia (2012) 2.78

The chemokine receptor CXCR-4 is expressed on CD34+ hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1. Blood (1998) 2.78

European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol (2004) 2.65

Retracted Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med (2000) 2.64

A PCR-oligonucleotide ligation assay to determine the prevalence of 23S rRNA gene mutations in clarithromycin-resistant Helicobacter pylori. Antimicrob Agents Chemother (1997) 2.63

Cognitive processes mediating behavioral change. J Pers Soc Psychol (1977) 2.46

Intermediate-dose intravenous methotrexate and mercaptopurine therapy for non-T, non-B acute lymphocytic leukemia of childhood: a Pediatric Oncology Group study. J Clin Oncol (1989) 2.21

Antibody to hepatitis C virus in German blood donors. Lancet (1989) 2.21

Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib. Ann Oncol (2010) 2.11

Identification of a 23S rRNA gene mutation in clarithromycin-resistant Helicobacter pylori. Helicobacter (1996) 2.10

[S3-Guidelines Conference "Colorectal Carcinoma" 2004]. Z Gastroenterol (2004) 2.03

Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood (2000) 2.00

Development of a standardized susceptibility test for campylobacter with quality-control ranges for ciprofloxacin, doxycycline, erythromycin, gentamicin, and meropenem. Microb Drug Resist (2004) 1.97

What is the value added by human intervention in protein structure prediction? Proteins (2001) 1.97

Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood (1994) 1.95

Association between human tumor colony-forming assay results and response of an individual patient's tumor to chemotherapy. Am J Med (1981) 1.92

Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. J Clin Oncol (2003) 1.86

Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. J Clin Oncol (2003) 1.82

High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J Clin Oncol (1996) 1.77

Human signal-regulatory protein is expressed on normal, but not on subsets of leukemic myeloid cells and mediates cellular adhesion involving its counterreceptor CD47. Blood (1999) 1.77

Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group. J Clin Oncol (2003) 1.75

Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol (2005) 1.71

Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med (2001) 1.71

Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. J Clin Oncol (1998) 1.68

Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: Perspectives in Colorectal Cancer, Dublin, 2001). Eur J Cancer (2002) 1.66

Single-agent carboplatinum for advanced seminoma. A phase II study. Cancer (1993) 1.63

Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP) Ann Oncol (1997) 1.63

Tight binding of clarithromycin, its 14-(R)-hydroxy metabolite, and erythromycin to Helicobacter pylori ribosomes. Antimicrob Agents Chemother (1994) 1.62

Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. Eur J Cancer (2009) 1.62

Acute cerebrovascular event after cisplatin-based chemotherapy for testicular cancer. Lancet (1991) 1.60

Analysis of factors contributing to higher erythropoietin levels in patients with chronic liver disease. Scand J Gastroenterol (2004) 1.60

Cytomegalovirus monitoring by polymerase chain reaction of whole blood samples from patients undergoing autologous bone marrow or peripheral blood progenitor cell transplantation. J Infect Dis (1997) 1.57

Cyclooxygenase-2: a novel target for cancer chemotherapy? J Cancer Res Clin Oncol (2001) 1.56

Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anticancer Drugs (1996) 1.56

Marked increase of the growth factors pleiotrophin and fibroblast growth factor-2 in serum of testicular cancer patients. Ann Oncol (2003) 1.53

Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study. Ann Oncol (2007) 1.52

Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood (1999) 1.52

[S3-guideline colorectal cancer version 1.0]. Z Gastroenterol (2013) 1.51

Irinotecan in the treatment of colorectal cancer: clinical overview. J Clin Oncol (2001) 1.50

The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. Cancer Res (2001) 1.50

Tumor marker kinetics predict outcome in patients with relapsed disseminated non-seminomatous germ-cell tumors. Ann Oncol (2012) 1.49

Deficient repair of cisplatin-DNA adducts identified in human testicular teratoma cell lines established from tumours from untreated patients. Eur J Cancer (1994) 1.49

Mobilization of peripheral blood progenitor cells by sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following polychemotherapy with etoposide, ifosfamide, and cisplatin. Blood (1992) 1.48

Cisplatin, etoposide, ifosfamide, vincristine and bleomycin combination chemotherapy for far advanced testicular carcinoma. Ann Oncol (1991) 1.47

Early detection of aspergillus infection after allogeneic stem cell transplantation by polymerase chain reaction screening. J Infect Dis (2000) 1.47

Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors. J Clin Oncol (1997) 1.46

Comparison of glycemic response and insulin requirements after mixed meals of equal carbohydrate content in healthy, type-1, and type-2 diabetic man. Klin Wochenschr (1989) 1.46

Absence of c-KIT and members of the epidermal growth factor receptor family in refractory germ cell cancer. Cancer (2002) 1.46

Primary central nervous system (CNS) lymphoma in immunocompetent patients. Ann Hematol (2002) 1.46

Identification of a novel viral protein in infectious bursal disease virus-infected cells. J Gen Virol (1995) 1.45

Participation of veterinarians in disaster management. J Am Vet Med Assoc (1997) 1.45

Interactive Volume Exploration of Petascale Microscopy Data Streams Using a Visualization-Driven Virtual Memory Approach. IEEE Trans Vis Comput Graph (2012) 1.45

Signal-regulatory protein alpha (SIRPalpha) but not SIRPbeta is involved in T-cell activation, binds to CD47 with high affinity, and is expressed on immature CD34(+)CD38(-) hematopoietic cells. Blood (2001) 1.44

In vivo effects of interleukin-6 on thrombopoiesis in healthy and irradiated primates. Blood (1992) 1.44

Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 1.43

Chemotherapy for germ cell tumors relapsing after high-dose chemotherapy and stem cell support: a retrospective multicenter study of the Austrian Study Group on Urologic Oncology. Ann Oncol (1997) 1.43

Aerobic exercise in the rehabilitation of cancer patients after high dose chemotherapy and autologous peripheral stem cell transplantation. Cancer (1997) 1.41

The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. Br J Cancer (2008) 1.41

Abnormal pentagastrin response in a patient with pseudohypoparathyroidism. Exp Clin Endocrinol Diabetes (2002) 1.40

Biocompatibility of alginates for grafting: impact of alginate molecular weight. Artif Cells Blood Substit Immobil Biotechnol (2003) 1.40

Hepatitis C viremia in German blood donors: serum alanine aminotransferase is not a valid marker for screening. Transfusion (1994) 1.40

Headache after hematopoietic stem cell transplantation: being aware of chronic bilateral subdural hematoma. Leuk Lymphoma (2006) 1.40

Molecular pathogenesis of Epstein-Barr virus associated posttransplant lymphomas: new insights through latent membrane protein 1 fingerprinting. Transplantation (2001) 1.39

Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells. Leukemia (1996) 1.38

[Predictive genetic investigations. Individualization of diagnosis and treatment in families with multiple endocrine neoplasia type II]. Dtsch Med Wochenschr (2000) 1.38

[68-year-old female patient with dyspnea and hypokalemic hypertension]. Internist (Berl) (2007) 1.38

[Therapy of diabetes in adults using Glibornurid. Results and clinical studies]. Dtsch Med Wochenschr (1973) 1.38

Molecular typing of Helicobacter pylori isolates from a multicenter U.S. clinical trial by ureC restriction fragment length polymorphism. J Clin Microbiol (1997) 1.37

Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases. Br J Cancer (2012) 1.35

A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974). Ann Oncol (2010) 1.33

Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor. Bone Marrow Transplant (2003) 1.31

Functional and phenotypic characterization of cord blood and bone marrow subsets expressing FLT3 (CD135) receptor tyrosine kinase. Blood (1997) 1.30

Induction of ribosome methylation in MLS-resistant Streptococcus pneumoniae by macrolides and ketolides. Microb Drug Resist (1999) 1.30

Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG) Br J Cancer (1994) 1.30

Axonal transport of adeno-associated viral vectors is serotype-dependent. Gene Ther (2012) 1.29

Ex vivo expansion of enriched peripheral blood CD34+ progenitor cells by stem cell factor, interleukin-1 beta (IL-1 beta), IL-6, IL-3, interferon-gamma, and erythropoietin. Blood (1993) 1.29

Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol (1996) 1.29

Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial. J Clin Oncol (1998) 1.29

Extragonadal seminoma: an international multicenter analysis of prognostic factors and long term treatment outcome. Cancer (2001) 1.29

Platinum organ toxicity and possible prevention in patients with testicular cancer. Int J Cancer (1999) 1.27

Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. Blood (2000) 1.26

Motivation to participate in cancer screening programmes. Soc Sci Med (1979) 1.26

Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection. Bone Marrow Transplant (2000) 1.26